BRAF and non-small cell lung carcinoma: Another study by Noeparast et al., investigated a patient cohort of NSCLC and demonstrated that non-V600 BRAF mutations, resulting in either high or impaired kinase activity, confer sensitivity to combined dabrafenib and trametinib treatment [32].